Xtant Medical (XTNT)
(Delayed Data from AMEX)
$0.74 USD
+0.03 (4.23%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.72 -0.02 (-2.70%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
XTNT 0.74 +0.03(4.23%)
Will XTNT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for XTNT based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for XTNT
Craig-Hallum Releases a Buy Rating on Xtant Medical Holdings (XTNT)
Xtant Medical Holdings, Inc. (XTNT) Q2 2024 Earnings Call Transcript
Analysts’ Top Healthcare Picks: Xtant Medical Holdings (XTNT), Tandem Diabetes Care (TNDM)
Xtant Medical to sell 7.8M shares at 64c in private placement
Xtant Medical reports Q2 EPS (3c) vs. (2c) last year